

Title (en)
PRIME EDITOR VARIANTS, CONSTRUCTS, AND METHODS FOR ENHANCING PRIME EDITING EFFICIENCY AND PRECISION

Title (de)
PRIME-EDITOR-VARIANTEN, KONSTRUKTE UND VERFAHREN ZUR VERBESSERUNG DER PRIME-EDITIERUNGSEFFIZIENZ UND -PRÄZISION

Title (fr)
VARIANTS D'ÉDITEUR PRIMAIRE, CONSTRUCTIONS ET PROCÉDÉS POUR AMÉLIORER L'EFFICACITÉ ET LA PRÉCISION D'UNE ÉDITION PRIMAIRE

Publication
EP 4274894 A2 20231115 (EN)

Application
EP 22702103 A 20220111

Priority

- US 202163136194 P 20210111
- US 202163176180 P 20210416
- US 202163176202 P 20210416
- US 202163194865 P 20210528
- US 202163194913 P 20210528
- US 202163231230 P 20210809
- US 202163255897 P 20211014
- US 2022012054 W 20220111

Abstract (en)
[origin: WO2022150790A2] The present disclosure provides compositions and methods for prime editing with improved editing efficiency and/or reduced indel formation by inhibiting the DNA mismatch repair path way while conducting prime editing of a target site. Accordingly, the present disclosure provides a method for editing a nucleic acid molecule by prime editing that involves contacting a nucleic acid molecule with a prime editor, a pegRNA, and an inhibitor of the DNA mismatch repair pathway, thereby installing one or more modifications to the nucleic acid molecule at a target site with increased editing efficiency and/or lower indel formation. The present disclosure further provides polynucleotides for editing a DNA target site by prime editing comprising a nucleic acid sequence encoding a napDNAbp, a polymerase, and an inhibitor of the DNA mismatch repair pathway, wherein the napDNAbp and polymerase is capable in the presence of a pegRNA of installing one or more modifications in the DNA target site with increased editing efficiency and/or lower indel formation. The disclosure further provides, vectors, cells, and kits comprising the compositions and polynucleotides of the disclosure. The present disclosure also provides compositions and methods for prime editing with improved editing efficiency and/or reduced indel formation with modified prime editor fusion proteins. The disclosure further provides, vectors, cells, and kits comprising the compositions and polynucleotides of the disclosure.

IPC 8 full level
C12N 15/11 (2006.01); **C12N 9/12** (2006.01); **C12N 9/22** (2006.01); **C12N 15/10** (2006.01)

CPC (source: EP)
C12N 9/1276 (2013.01); **C12N 9/22** (2013.01); **C12N 15/102** (2013.01); **C12N 15/111** (2013.01); **C12Y 207/07049** (2013.01); **C12Y 301/00** (2013.01); **C12N 2310/20** (2017.04); **C12N 2310/3519** (2013.01)

Citation (search report)
See references of WO 2022150790A2

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

Designated validation state (EPC)
KH MA MD TN

DOCDB simple family (publication)
WO 2022150790 A2 20220714; **WO 2022150790 A3 20220811**; AU 2022206476 A1 20230720; CA 3203876 A1 20220714; EP 4274894 A2 20231115; JP 2024503437 A 20240125

DOCDB simple family (application)
US 2022012054 W 20220111; AU 2022206476 A 20220111; CA 3203876 A 20220111; EP 22702103 A 20220111; JP 2023542569 A 20220111